Is This Inhaler Effective for Respiratory Viruses?

Budesonide, an inhaled glucocorticoid often used by people with asthma and COPD, was effective in improving COVID-19 outcomes when administered within the first seven days of the onset of symptoms.

Originally published on 3/17/21

STORY AT-A-GLANCE

• Researchers conducted a randomized trial to determine if budesonide, when used early during COVID-19 infection, would improve outcomes

• Inhaled budesonide lowered the relative risk of needing urgent care or hospitalization by 90% over 28 days, while also resolving fever and other symptoms faster and leading …